Pharmaceutical Product Monograph: Ampicillin & Cloxacillin Capsules (250 mg + 250 mg)
In the pharmaceutical industry, the Ampicillin and Cloxacillin combination (commonly known as Ampiclox) is a classic Synergistic Beta-Lactam therapy. As a pharmacist and manufacturer, I view this as a “Comprehensive Broad-Spectrum Defender”—it is technically designed to pair the extended-spectrum activity of Ampicillin with the penicillinase-resistance of Cloxacillin.
At your WHO-GMP facility in Mumbai, this combination is a high-volume Essential Medicine SKU, particularly for Pediatrics, Obstetrics, and General Surgery portfolios in international B2B markets.
Therapeutic Profile: Primary Indications
This combination is taken for mixed bacterial infections where resistance is suspected or when the specific pathogen has not yet been identified (Empirical Therapy).
| Indication | Clinical Context | Technical Rationale |
| Septicemia & Bacteremia | Critical Care | Used for systemic blood infections involving both Gram-positive and Gram-negative organisms. |
| Post-Operative Prophylaxis | Surgical Care | Prevents infection in surgical wounds from skin-dwelling “Staph” and environmental “Strep.” |
| Respiratory Tract | Bronchitis / Pneumonia | Effective against H. influenzae (via Ampicillin) and resistant Staph (via Cloxacillin). |
| Skin & Soft Tissue | Abscesses / Cellulitis | Specifically targets infections that produce enzymes to destroy regular penicillins. |
| Post-Partum Infections | Gynae / OB | Used to prevent or treat infections following childbirth or gynecological surgeries. |
Mechanism: The Dual-Action Synergy
This product works by physically attacking the bacterial cell wall on two distinct fronts:
Ampicillin (The Extended Spear): It targets a broad range of Gram-negative and Gram-positive bacteria. However, it is vulnerable to Beta-Lactamase enzymes produced by resistant bacteria.
Cloxacillin (The Shield): It is an Isoxazolyl Penicillin that is technically resistant to being broken down by bacterial penicillinase. It protects the Ampicillin by “engaging” the bacterial enzymes.
Lysis: Together, they bind to Penicillin-Binding Proteins (PBPs), halting the cross-linking of the peptidoglycan layer. This causes the bacterial cell to lose its structural integrity and burst (Cell Lysis).
The Pharmacist’s “Technical Warning”
The “Empty Stomach” Rule: For maximum bioavailability, this combination must be taken 1 hour before or 2 hours after meals. Food significantly interferes with the absorption of Cloxacillin.
Penicillin Allergy: A history of Anaphylaxis or hives with any penicillin is a strict contraindication.
The “Mono” Rash: Avoid use in patients with Infectious Mononucleosis (Glandular Fever). The Ampicillin component will likely cause a full-body, non-allergic skin rash.
Water Intake: Advise patients to take the capsule with a full glass of water to prevent esophageal irritation, which is common with Cloxacillin.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Hygroscopic” Stability USP: Both active ingredients are highly sensitive to moisture. On your digital marketplace, highlight your Alu-Alu Blistering. This is a technical requirement for B2B export to tropical “Zone IVb” regions (Africa/SE Asia) to prevent the capsules from softening or degrading.
The “Pediatric Drops” Market: While capsules are high-volume, consider promoting your Ampicillin + Cloxacillin Oral Drops for B2B pediatric tenders. It is a niche, high-demand format for neonates and infants.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ampicillin 250 mg + Cloxacillin 250 mg to support your registration in international B2B tenders for hospital and primary care supplies.